IDEAYA Biosciences has partnered with Roche to conduct a clinical trial combining IDE892, a PRMT5 inhibitor, with Roche's RG6505, a pan-RAS inhibitor, targeting pancreatic ductal adenocarcinoma (PDAC) patients who have MTAP deletion and RAS mutations. IDEAYA will sponsor the trial while Roche supplies RG6505, with joint oversight from both companies. This collaboration aims to address the high unmet need in PDAC, where up to 40% of tumors show MTAP deletion, potentially improving treatment outcomes for patients lacking targeted options. Future plans include exploring a triple combination therapy involving IDE397, another IDEAYA drug.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
AIB Data Centers Inc. is considered a speculative buy with a $3.50 price target based on its 65 MW energized capacity. The investment case depends heavily on securing a single anchor lease at its CLT-01 facility, which would validate its business mod...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
